Riccardo Perfetti - Jun 28, 2021 Form 4 Insider Report for Applied Therapeutics Inc. (APLT)

Signature
/s/ Shoshana Shendelman, Attorney-in-Fact
Stock symbol
APLT
Transactions as of
Jun 28, 2021
Transactions value $
-$96,850
Form type
4
Date filed
6/30/2021, 09:00 PM
Previous filing
Jun 7, 2021
Next filing
Jul 15, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLT Common Stock Options Exercise $5.11K +3.55K $1.44 3.55K Jun 28, 2021 Direct F1
transaction APLT Common Stock Sale -$7.91K -360 -10.15% $21.96* 3.19K Jun 28, 2021 Direct F2, F3
transaction APLT Common Stock Sale -$46.7K -1.99K -62.35% $23.51* 1.2K Jun 28, 2021 Direct F2, F4
transaction APLT Common Stock Sale -$28.8K -1.2K -100% $24.01* 0 Jun 28, 2021 Direct F2, F5
transaction APLT Common Stock Options Exercise $662 +460 $1.44 460 Jun 29, 2021 Direct F1
transaction APLT Common Stock Sale -$10K -460 -100% $21.76* 0 Jun 29, 2021 Direct F2, F6
transaction APLT Common Stock Options Exercise $662 +460 $1.44 460 Jun 30, 2021 Direct F1
transaction APLT Common Stock Sale -$3.33K -160 -34.78% $20.80* 300 Jun 30, 2021 Direct F2, F7
transaction APLT Common Stock Sale -$6.51K -300 -100% $21.71* 0 Jun 30, 2021 Direct F2, F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLT Stock Option (Right to Buy) Options Exercise $0 -3.55K -2.09% $0.00 166K Jun 28, 2021 Common Stock 3.55K $1.44 Direct F1, F9
transaction APLT Stock Option (Right to Buy) Options Exercise $0 -460 -0.28% $0.00 166K Jun 29, 2021 Common Stock 460 $1.44 Direct F1, F9
transaction APLT Stock Option (Right to Buy) Options Exercise $0 -460 -0.28% $0.00 165K Jun 30, 2021 Common Stock 460 $1.44 Direct F1, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Compensatory options granted under Applied Therapeutics, Inc.'s 2016 Equity Incentive Plan, exercised automatically pursuant to the reporting person's written trading plan previously entered into on September 16, 2020, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2 Automatic sales made pursuant to the reporting person's pre-existing written trading plan, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F3 Weighted average price. These shares were sold in multiple transactions at prices ranging from $21.7000 to $22.1800 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 Weighted average price. These shares were sold in multiple transactions at prices ranging from $22.8600 to $23.8400 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5 Weighted average price. These shares were sold in multiple transactions at prices ranging from $23.8600 to $24.1300 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F6 Weighted average price. These shares were sold in multiple transactions at prices ranging from $21.4700 to $22.0000 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F7 Weighted average price. These shares were sold in multiple transactions at prices ranging from $20.6200 to $20.9000 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F8 Weighted average price. These shares were sold in multiple transactions at prices ranging from $21.6300 to $21.7900 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F9 Thirty-three percent (33%) of the shares subject to the option vested on August 27, 2018, and one twenty-fourth (1/24th) of the remaining shares subject to the Option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.